好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2017 Annual Meeting | C190 - Multiple Sclerosis Overview III: Basic and Translational Science

Thursday 04/27/17
07:00 AM - 09:00 AM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Seminar
Michael K. Racke, MD
General Neurology
Participants should be able to identify steps in MS pathogenesis, treatments used in MS management, and how approved therapies affect the immune response and potential complications resulting from those interventions.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Trainee, General Neurologist, Specialist Neurologist
Didactic
Event Timeline
07:00 AM - 07:45 AM Speaker MS Pathogenesis
Olaf Stuve, MD, PhD, FAAN
07:45 AM - 08:30 AM Speaker Mechanism of MS Therapies and Their Use
Michael K. Racke, MD
08:30 AM - 09:00 AM Q&A Questions and Answers
Faculty Disclosures
Michael K. Racke, MD Dr. Racke has received personal compensation for serving as an employee of Quest Diagnostics. Dr. Racke has stock in Quest Diagnostics. Dr. Racke has received intellectual property interests from a discovery or technology relating to health care.
Olaf Stuve, MD, PhD, FAAN Dr. Stuve has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Stuve has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Therapeutic Advances in Neurological Diseases. Dr. Stuve has received research support from US Department of Veterans Affairs. Dr. Stuve has received research support from National Multiple Sclerosis Society (US). Dr. Stuve has received research support from Merck KGaA.